Company intelligence / Profile preview

Ophthalmology NewCo

Austin, Texas, United Stateskxan.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Announced as a new ophthalmology-focused entity to be spun out from Ascendis Pharma with institutional investor backing. No clinical results disclosed yet.

Therapeutic areas: Ophthalmology
Modalities: ophthalmic therapeuticsdrug delivery
Industry: Biotech

Partnerships

Institutional investors involved in financing at launch

Beyond the preview

Go deeper on Ophthalmology NewCo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ophthalmology NewCo.

Explore the full profile